Specialty drug delivery technologies

Solid oral and topical dosage forms

A pharmaceutical CDMO you can trust

First time in man acceleration

A CDMO that will earn your confidence.

A scientist to lead your project, full analytical support to keep it on track, and a veteran team to complete it successfully. That’s the Metrics promise.

Investments expand capabilities.

Metrics expands with new fast-track product development laboratory and Gerteis Mini-Pactor®.

Specialty Technologies? Meet Metrics.

Our proprietary advanced drug delivery technologies are available through licensing or co-development arrangements. What problem can we help you solve?

Accelerated FTIM timeline?
No problem.

Having successfully completed more than 130 fast-track studies, Metrics has a solid reputation for meeting FTIM and Phase I deadlines.

Pharmaceutical drug product development

Metrics delivers pharmaceutical formulation development for routine or complex compounds, first time in man (FTIM) and fast-track development for a variety of dosage forms.

Learn more.

Method development, validation and stability testing

Metrics’ cGMP analytical testing facility has dedicated labs for stability studies, raw materials, trace metals, and microbiology.

Learn more.

CTM Manufacturing and commercial manufacturing

Metrics extends its scientist-led development and analytical testing of solid oral dose formulations into manufacturing for  Phase I, II and III clinical trial material and commercialization.

Learn more.

Sample Submittal Form

Sending a sample to Metrics?
Use this form to record your sample, storage and testing information.

Download

Metrics Scientist Awarded Patent

Dr. Brad Gold, vice president of pharmaceutical development, has received a U.S. patent for his intellectual property about controlled release technology. The U.S. Patent and Trademark Office awarded Gold a patent (No. 8,858,993) for his application, “Coated tablets with zero-order or near zero-order release kinetics.”

Learn more

Metrics Inc. Expands with Fast-Track Product Development Laboratory

Along with Gerteis Mini-Pactor®, capital investments reflect ongoing commitment to contract services

Learn more

Cleantaste™

Our new proprietary technology can improve the taste and stability of tablets; deliver sustained release characteristics.

Learn more

SUBA™ for enhanced bioavailability

Benefits of this new proprietary technology include improved and consistent drug absorption.

Learn more

Metrics Offers Proprietary Pellet Forms

Metrics Inc. now offers proprietary pellet technologies enabling controlled release to help support therapeutic effectiveness of active pharmaceutical ingredients (API).

Learn more

Using Quality by Design to Improve Tablet Strength
and Friability

Joe Cobb and his team used the principles of QbD to improve the robustness of a core tablet for a novel modified release oral solid dosage form. View the AAPS 2012 poster and watch a short video about how Metrics applies the principles of QbD to solve formulation development issues.

Read Poster

Metrics expands capabilities for Phase I clinical trial materials

Metrics’ potent facility now offers neat API Capsule Filling. The completely contained Xcelodose® could help accelerate clients’ move to Phase I clinical trials.

Learn More